Last updated: 2026-09-05 03:24:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Jasper Therapeutics, Inc. (JSPR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.71, with a market capitalization of $23.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.32 to $2.78. This page covers its latest market performance, valuation, price trends and company information.
$23.46M | |
$0.67 | |
$188.80 | |
$0.32 | |
$0.69 | |
430.37K | |
-- | |
-- | |
$2.78 | |
$0.32 | |
-- | |
-- |
Jasper Therapeutics, Inc. (JSPR) last closed at $0.69 as of 2026-09-04 23:52:00, unchanged from the previous close of $0.69.
During the latest regular trading session, JSPR traded between $0.32 and $188.80, with a volume of 430.37K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Jasper Therapeutics, Inc. (JSPR) moved from $0.71 to $0.71, representing a decline of 0.55% ($0.00).
The stock traded between $0.67 and $0.71 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 420.43 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.1%
JSPR is currently trading at $0.71, placing it 16.1% of the way from its 52-week low of $0.32 to its 52-week high of $2.78. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Jasper Therapeutics, Inc. (JSPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.